Affimed N.V. logo
Affimed N.V. AFMD
report update icon

Quarterly report 2024-Q2
added 05-23-2026

Affimed N.V. Financial Statements 2023-2011 | AFMD

Annual Financial Statements Affimed N.V.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 527 M 473 M 152 M 212 M 93 M 66.5 M 90.8 M 136 M - - -

Shares

- - 120 M 83.5 M 64.2 M 60.5 M 43.7 M 33.3 M 28.5 M 24 M - - -

Historical Prices

- - 4.41 5.67 2.36 3.51 2.12 2 3.19 6.17 - - -

Net Income

-106 M -86 M -57.5 M -41.4 M -32.4 M -19.5 M -30.2 M -32.2 M -20.2 M -260 K -26.1 M -14.3 M -

Revenue

8.28 M 41.4 M 40.4 M 28.4 M 21.4 M 23.7 M 2.01 M 6.31 M 7.56 M 3.38 M 5.09 M 1.17 M -

Gross Profit

- - - - 19.8 M 22.6 M 1.02 M 5.29 M 6.66 M 2.54 M 4.38 M 620 K -

Operating Income

-107 M -88.1 M -64 M -34.7 M -32.4 M -19.5 M -27.3 M -32 M -21.3 M - - - -

EBITDA

-107 M -88.1 M -64 M -34.7 M -32.4 M -19.5 M -27.3 M -32 M -21.3 M -7.74 M -15.3 M -9.99 M -

Operating Expenses

- - - - 54 M 43.3 M 29.3 M 38.4 M 28.9 M 11.6 M 20.8 M 11.6 M -

General and Administrative Expenses

24.7 M 32.1 M 24.2 M 13.7 M 10.3 M 9.64 M 7.99 M 8.32 M 7.55 M 2.35 M 7.05 M 3.05 M -

All numbers in EUR currency

Quarterly Income Statement Affimed N.V.

2024-Q2 2023-Q4 2023-Q3 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

15.3 M - - 149 M - - 147 M - 120 M - 120 M - 83.5 M - 79.2 M - 64.2 M - 62.4 M - 60.5 M - 62.4 M - 43.7 M - - - 33.3 M - - - 28.5 M - - - - - - - - - - - - - - - - - - -

Net Income

-15.5 M -106 M - -29.4 M - - -19.4 M - -57.5 M - -18.8 M - -41.4 M - -12.2 M - -32.4 M - -10.3 M - -19.5 M - -8.01 M - -30.2 M - - - -32.2 M - - - -20.2 M - - - - - - - - - - - - - - - - - - -

Revenue

154 K 8.28 M - 1.39 M - - 7.3 M - 40.4 M - 9.71 M - 28.4 M - 2.93 M - 21.4 M - 4.01 M - 23.7 M - 150 K - 2.01 M - - - 6.31 M - - - 7.56 M - - - - - - - - - - - - - - - - - - -

Operating Income

-15.6 M -107 M - -29.4 M - - -21.7 M - -64 M - -17.2 M - -34.7 M - -11.3 M - -32.4 M - -9.68 M - -19.5 M - -9.11 M - -27.3 M - - - -32 M - - - -21.3 M - - - - - - - - - - - - - - - - - - -

EBITDA

-15.6 M -107 M - -29.4 M - - -21.7 M - -64 M - -17.2 M - -34.7 M - -11.3 M - -32.4 M - -9.68 M - -19.5 M - -9.11 M - -27.3 M - - - -32 M - - - -21.3 M - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.04 M 24.7 M - 6.28 M - - 8.37 M - 24.2 M - 5.44 M - 13.7 M - 2.61 M - 10.3 M - 2.34 M - 9.64 M - 2.16 M - 7.99 M - - - 8.32 M - - - 7.55 M - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Affimed N.V. AFMD
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Affimed N.V. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
$ 263.04 0.49 % $ 465 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.41 2.15 % $ 3.41 B canadaCanada
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.53 6.02 % $ 678 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.09 3.74 % $ 139 M schweizSchweiz
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 8.61 0.16 % $ 2.05 B usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
- - $ 643 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
- - $ 2.6 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
- - $ 154 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain